Status:
UNKNOWN
Selenium Treatment and Chagasic Cardiopathy (STCC)
Lead Sponsor:
Oswaldo Cruz Foundation
Collaborating Sponsors:
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Ministry of Health, Brazil
Conditions:
Chagas Disease
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
Background: Chagasic myocardiopathy caused by the protozoa Trypanosoma cruzi has been the principal cause of cardiac death in Latin America. Without any trypanocidal therapeutic intervention, infecte...
Detailed Description
Several induced cardiomyopathy , Mycoplasma pneumonia-induced myocarditis, heart damage investigations have shown positive effects of Se on experimental models: cardiotoxicity induced by chemotherapic...
Eligibility Criteria
Inclusion
- altered ECHO (LVEF between 0,35 % and 45 %)
- age between 20 and 65 years
Exclusion
- patients \> 65 years of age
- smoke habit, patients with non-chagasic cardiopathy, live close to mineral deposit, metals industries and place with radioactive exposition, vegetarian
- depressive psychological profile
- pregnant or in lactating period
- present or presented cancer or diabetes.
- patients will be excluded if they take anti-convulsive medicines (Clozapine, Valproic Acid)
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT00875173
Start Date
October 1 2008
End Date
December 1 2020
Last Update
November 10 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Nacional de Infectologia/Instituto de Pesquisa Clínica Evandro Chagas
Rio de Janeiro, Rio de Janeiro, Brazil, 21040-360